Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Kronos Bio Inc (KRON)

Kronos Bio Inc (KRON)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 57,691
  • Shares Outstanding, K 60,095
  • Annual Sales, $ 6,290 K
  • Annual Income, $ -112,670 K
  • 60-Month Beta 1.82
  • Price/Sales 9.08
  • Price/Cash Flow N/A
  • Price/Book 0.35
Trade KRON with:
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -1.95
  • Most Recent Earnings $-0.43 on 03/21/24
  • Latest Earnings Date 05/08/24
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Options Overview Details

View History
  • Implied Volatility 585.58% ( +330.79%)
  • Historical Volatility 55.64%
  • IV Percentile 96%
  • IV Rank 38.71%
  • IV High 1,466.97% on 03/15/24
  • IV Low 28.89% on 07/19/23
  • Put/Call Vol Ratio 0.00
  • Today's Volume 4
  • Volume Avg (30-Day) 84
  • Put/Call OI Ratio 0.00
  • Today's Open Interest 2,377
  • Open Int (30-Day) 1,398

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/24
See More
  • Average Estimate -0.46
  • Number of Estimates 3
  • High Estimate -0.34
  • Low Estimate -0.55
  • Prior Year -0.46
  • Growth Rate Est. (year over year) unch

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.9000 +8.89%
on 04/23/24
1.3800 -28.99%
on 04/01/24
-0.2500 (-20.33%)
since 03/25/24
3-Month
0.9000 +8.89%
on 04/23/24
1.4000 -30.00%
on 03/11/24
-0.1800 (-15.52%)
since 01/25/24
52-Week
0.7310 +34.06%
on 11/14/23
2.2900 -57.21%
on 07/13/23
-0.3500 (-26.32%)
since 04/25/23

Most Recent Stories

More News
Kronos Bio, Inc. (KRON) Reports Q1 Loss, Misses Revenue Estimates

Kronos Bio, Inc. (KRON) delivered earnings and revenue surprises of -6.98% and 89.15%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

KRON : 0.9800 (+2.08%)
IKNA : 1.3100 (+1.55%)
Here's Why Kronos Bio, Inc. (KRON) is Poised for a Turnaround After Losing 31% in 4 Weeks

Kronos Bio, Inc. (KRON) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising...

KRON : 0.9800 (+2.08%)
Here's Why Kronos Bio, Inc. (KRON) is Poised for a Turnaround After Losing 23.8% in 4 Weeks

Kronos Bio, Inc. (KRON) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising...

KRON : 0.9800 (+2.08%)
Kronos Bio and Invivoscribe Partner on Companion Diagnostic for Use with Entospletinib, Kronos Bio's Investigational Compound Being Developed for Patients with AML

/PRNewswire/ -- Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer, and Invivoscribe, a global provider...

KRON : 0.9800 (+2.08%)
Kronos Bio and Invivoscribe Partner on Companion Diagnostic for Use with Entospletinib, Kronos Bio's Investigational Compound Being Developed for Patients with AML

/CNW/ -- Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer, and Invivoscribe, a global provider of...

KRON : 0.9800 (+2.08%)
Can Kronos Bio, Inc. (KRON) Climb 312% to Reach the Level Wall Street Analysts Expect?

The consensus price target hints at a 311.9% upside potential for Kronos Bio, Inc. (KRON). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings...

KRON : 0.9800 (+2.08%)
Kronos Bio, Inc. (KRON) Upgraded to Buy: Here's What You Should Know

Kronos Bio, Inc. (KRON) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

KRON : 0.9800 (+2.08%)
Kronos Bio Continues to Advance Investigational SYK Inhibitors Entospletinib and Lanraplenib with New Preclinical Data at EHA2022 Congress

Posters include preclinical data on SYK inhibition in combination with targeted agents suggesting evidence of preclinical anti-tumor activity in acute...

KRON : 0.9800 (+2.08%)
Kronos Bio’s Investigational SYK Inhibitors Entospletinib and Lanraplenib to be Featured in Four Poster Presentations at EHA2022 Congress

Posters include preclinical data on SYK inhibition in combination with targeted agents and demonstrate preclinical anti-tumor activity in acute myeloid...

KRON : 0.9800 (+2.08%)
Will Insiders Be Tempted To Buy More KRON At The New 52-Week Low?

In trading on Thursday, shares of Kronos Bio Inc touched a new 52-week low of $6.04/share. That's a $22.38 share price drop, or -78.75% decline from the 52-week high of $28.42 set back on 06/08/2021....

KRON : 0.9800 (+2.08%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Sell with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More Share

Business Summary

Kronos Bio Inc. is a clinical-stage biopharmaceutical company. It engages in discovery and development of novel cancer therapeutics designed to transform patient outcomes by targeting dysregulated transcription. Kronos Bio Inc. is headquartered in San Mateo, Calif.

See More

Key Turning Points

3rd Resistance Point 1.0400
2nd Resistance Point 1.0200
1st Resistance Point 1.0000
Last Price 0.9800
1st Support Level 0.9600
2nd Support Level 0.9400
3rd Support Level 0.9200

See More

52-Week High 2.2900
Fibonacci 61.8% 1.6945
Fibonacci 50% 1.5105
Fibonacci 38.2% 1.3265
Last Price 0.9800
52-Week Low 0.7310

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar